As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is continuing working around the clock to research, develop and manufacture vaccines to prevent infection. To date, substantial progress has been made in vaccinating Americans with COVID-19 vaccines that have been granted emergency use authorization (EUA) by the U.S. Food … Continued
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have made unprecedented progress in advancing treatments and vaccines to help fight COVID-19. At this time, three vaccines and several treatments have received emergency use authorizations (EUAs) from the U.S. Food and … Continued
When the pandemic began, America’s biopharmaceutical companies immediately started to develop solutions to help diagnose, treat and prevent COVID-19 infection. While authorized vaccines provide hope that this pandemic may soon be over, the biopharmaceutical industry is preparing for the next public health emergency. PhRMA′s CEO, Stephen J. Ubl, will share lessons the biopharmaceutical has learned … Continued
On September 8, Pharmaceutical Research and Manufacturers of America President and CEO Stephen J. Ubl made the following statement: “The biopharmaceutical industry is confident we can beat COVID-19 because science guides every aspect of our work. Our industry is committed to ensuring the highest of standards of research, clinical testing and manufacturing are upheld throughout … Continued
As the fight to research and develop innovative treatments and vaccines advances, three biopharmaceutical scientists share what they have in common: combatting COVID-19.
The biopharmaceutical industry is committed to the discovery and the development of treatments and development of vaccines for infectious diseases, despite their complicated nature. A new report finds that there are 421 medicines and vaccines in clinical development to treat or prevent bacterial and viral infections that cause infectious diseases, including COVID-19.
In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19, a disease caused by a novel strain of coronavirus. Our companies are working around the clock to research and develop new vaccines and treatments, as well as testing existing medicines to help those infected with the virus. In … Continued
Just as you are doing your part to fight the novel coronavirus, America’s Biopharmaceutical Companies are working around the clock to fight COVID-19. Click to watch video.
A new infographic from PhRMA illustrates how America’s biopharmaceutical companies are utilizing diagnostics, existing medicines, new treatments, manufacturing, and vaccines for one shared goal: Fighting COVID-19.
More than half of PhRMA members have R&D for potential treatments and vaccines under way or are providing donations of medicines and critical medical supplies as well as providing financial donations to support patients and first responders in addressing this evolving crisis.